U.S. nurses and physicians’ assistants prescribe antibody-based disease-modifying therapies to their multiple sclerosis patients more than neurologists do, a survey indicates.
The trend has been for the doctors to stick with interferon therapies, the study said.
Antibody-based disease-modifying therapies are also known as monoclonal antibodies. They are designed to harness the immune system to slow down or stop the destruction of myelin, the protective coating around nerve cells.
Spherix Global Insights conducted the survey, whose findings it presented in the report “RealTime Dynamix: Advanced Practice Providers in Multiple Sclerosis (US).”
The annual report provides information about healthcare practitioners’ familiarity with and use of treatments, what therapies they are using more of and less of, and their awareness of therapies in the development pipeline, according to a Spherix press release.
Fifty-three nurses and physicians’ assistants participated in this year’s survey. Spherix compared the results with those from a survey of 98 neurologists. That report was titled “RealTime Dynamix: Multiple Sclerosis (US).”
Nurses and physicians’ assistants are an important care and support group for MS patients. They spend most of their time overseeing patients, including helping relapsing MS patients manage their often complex situations.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?